Table 2 depicts that among the 59 cases of endometrial carcinoma, 33 (55.93%), 44 (74.57%), six (10.10%), and 38 (64.40%) patients were observed to be ER, PR, HER2/neu, and BCL-2 receptor positive (Figure 2). This evidence concerns the gene ESR1 and endometrial carcinoma.